Related Experiment Video
Updated: Nov 25, 2025
A Scalable, Cell-Based Method for the Functional Assessment of Ube3a Variants
Published on: October 10, 2022
Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice
Timothy J Humpton1,2, Koji Nomura2, Julia Weber1
1The Francis Crick Institute, London NW1 1AT, United Kingdom.
Abstract:
The p53 tumor suppressor protein is a potent activator of proliferative arrest and cell death. In normal cells, this pathway is restrained by p53 protein degradation mediated by the E3-ubiquitin ligase activity of MDM2. Oncogenic stress releases p53 from MDM2 control, so activating the p53 response. However, many tumors that retain wild-type p53 inappropriately maintain the MDM2-p53 regulatory loop in order to continuously suppress p53 activity. We have shown previously that single point mutations in the human MDM2 RING finger domain prevent the interaction of MDM2 with the E2/ubiquitin complex, resulting in the loss of MDM2's E3 activity without preventing p53 binding. Here, we show that an analogous mouse MDM2 mutant (MDM2 I438K) restrains p53 sufficiently for normal growth but exhibits an enhanced stress response in vitro. In vivo, constitutive expression of MDM2 I438K leads to embryonic lethality that is rescued by p53 deletion, suggesting MDM2 I438K is not able to adequately control p53 function through development. However, the switch to I438K expression is tolerated in adult mice, sparing normal cells but allowing for an enhanced p53 response to DNA damage. Viewed as a proof of principle model for therapeutic development, our findings support an approach that would inhibit MDM2 E3 activity without preventing MDM2/p53 binding as a promising avenue for development of compounds to activate p53 in tumors with reduced on-target toxicities.
Insights
Targeting MDM2
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The p53 tumor suppressor protein regulates cell death and proliferation.
- MDM2 inhibits p53 activity through protein degradation, a crucial mechanism in normal cells.
- Cancer cells often exploit the MDM2-p53 interaction to suppress p53, even with wild-type p53.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting MDM2's E3 ligase activity while preserving p53 binding.
- To evaluate a specific mouse MDM2 mutant (I438K) as a model for this therapeutic strategy.
Main Methods:
- Generated a mouse model expressing an MDM2 mutant (I438K) with impaired E3 ligase activity but intact p53 binding.
- Assessed the in vitro and in vivo effects of MDM2 I438K on p53 activity and organismal development.
- Utilized p53 deletion to rescue embryonic lethality in the MDM2 I438K mouse model.
Main Results:
- The MDM2 I438K mutant restrains p53 for normal growth but enhances stress responses in vitro.
- Constitutive MDM2 I438K expression causes embryonic lethality, rescued by p53 deletion, indicating developmental p53 control is essential.
- Adult mice tolerate MDM2 I438K expression, showing normal cell sparing and enhanced p53 activation upon DNA damage.
Conclusions:
- Inhibiting MDM2 E3 ligase activity, without disrupting p53 binding, is a viable strategy for p53 activation in cancer.
- This approach offers a promising therapeutic avenue for tumors with wild-type p53, potentially with reduced on-target toxicities.
- The MDM2 I438K mouse model serves as a proof-of-principle for developing drugs that selectively target MDM2's ligase function.
